Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bossen

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Plos One|March 29, 2024
High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trialPalle Bager, Lars Bossen, Rasmus Gantzel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 18, 2026
Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of CirrhosisLars Bossen, Henning Grønbæk, Peter Ott, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 21, 2017
Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population-based studyLars Bossen, Henning Grønbaek, Peter Lykke Eriksen, et al.
Journal of Gastroenterology and Hepatology|December 1, 2018
Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascitesLars Bossen, Pere Ginès, Hendrik Vilstrup, et al.
Hepatology (Baltimore, Md.)|November 25, 2015
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patientsLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
Hepatology (Baltimore, Md.)|March 27, 2016
ReplyLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Diabetes does not increase infection risk or mortality following an infection in patients with cirrhosis and ascitesLars Bossen, Gitte A Dam, Hendrik Vilstrup, et al.
Ugeskrift for Laeger|March 15, 2018
[New name and new treatments for primary biliary cholangitits]Lars Bossen, Henriette Ytting, Peter Jepsen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2018
Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascitesGitte Dam, Hendrik Vilstrup, Per Kragh Andersen, et al.
Autoimmunity Reviews|July 15, 2018
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markersLars Bossen, Alessio Gerussi, Vasiliki Lygoura, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Plos One|March 29, 2024
High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trialPalle Bager, Lars Bossen, Rasmus Gantzel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 18, 2026
Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of CirrhosisLars Bossen, Henning Grønbæk, Peter Ott, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 21, 2017
Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population-based studyLars Bossen, Henning Grønbaek, Peter Lykke Eriksen, et al.
Journal of Gastroenterology and Hepatology|December 1, 2018
Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascitesLars Bossen, Pere Ginès, Hendrik Vilstrup, et al.
Hepatology (Baltimore, Md.)|November 25, 2015
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patientsLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
Hepatology (Baltimore, Md.)|March 27, 2016
ReplyLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Diabetes does not increase infection risk or mortality following an infection in patients with cirrhosis and ascitesLars Bossen, Gitte A Dam, Hendrik Vilstrup, et al.
Ugeskrift for Laeger|March 15, 2018
[New name and new treatments for primary biliary cholangitits]Lars Bossen, Henriette Ytting, Peter Jepsen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2018
Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascitesGitte Dam, Hendrik Vilstrup, Per Kragh Andersen, et al.
Autoimmunity Reviews|July 15, 2018
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markersLars Bossen, Alessio Gerussi, Vasiliki Lygoura, et al.
Pageof 3